Tiltan Pharma Company

Tiltan Pharma is an Israeli biopharmaceutical company, established in 2006, that developed a proprietary anti-angiogenic and immune modulatory platform technology, for the treatment of cancer. The platform technology was originally developed by Prof. Shmuel (Muli) Ben Sasson from the Hebrew University.
Technology: P4 Medicine
Industry: Preventive Medicine
Headquarters: Jerusalem, Israel
Founded Date: 2006
Employees Number: 1-10
Funding Status: N/A
Total Funding: $1.5M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership